Candida vulvovaginitis

(Redirected from Candida Vaginitis)

Background

Labeled vulva, showing external and internal views.
Pelvic anatomy including organs of the female reproductive system.
  • Local fungal infection caused by the Candida genus (most commonly Candida albicans)
  • Most commonly seen in females in high estrogen states: pregnancy, oral contraceptive use, obesity, diabetes mellitus
  • Not considered an STI although it can be transmitted by sexual intercourse
  • May occur in premarnarcheal girls (rare)
  • Can occur as a result of antibiotic use

Types[1]

  • Uncomplicated (must have all)
    • Sporadic infection
    • Mild-moderate symptoms
    • Due to Candida albicans (suspected or proven)
    • Immunocompetent
  • Complicated (presence of ANY of the following)
    • Any species other than C. albicans
    • Recurrent infection (defined as ≥4 episodes per year)
    • Severe symptoms or findings
    • Poorly controlled diabetes, immunocompromising conditions (such as HIV), debilitation, or immunosuppressive therapy (e.g., corticosteroids)

Clinical Features

Candida vaginitis

Differential Diagnosis

Vulvovaginitis

Evaluation

KOH test on a vaginal wet mount, showing slings of pseudohyphae of Candida albicans surrounded by round vaginal epithelial cells.

Work-up

  • Urine pregnancy
  • Wet mount
  • Consider blood glucose (if recurrent, to check for occult DM)
  • Consider tests for STIs

Diagnosis

  • Cotton cheese curd-like non-odorous vaginal discharge on pelvic exam
  • Vaginal pH < 4.5
  • Vaginal wet mount
    • Hyphae and yeast buds
    • Candida does not cause WBCs on wet mount → if present, consider co-infection with other vaginitides or STI

Management

  • Do not treat if asymptomatic
  • Sexual partners should not be treated unless the patient has frequent recurrences
  • Does not need a test of cure

Antifungals

Uncomplicated

There is little resistance to azole medications; treatment often dictated by patient preference.

  • Fluconazole 150mg PO once (preferred)[3]
    • A second dose at 72hrs may be given if patient is still symptomatic
  • Intravaginal therapy
    • Clotrimazole 1 % cream applied vaginally for 7 days OR
    • Clotrimazole 2% applied vaginally for 3 days
    • Miconazole 2% cream applied vaginally for 7 days OR 4% cream x 3 days
    • Butoconazole 2% applied vaginally x 3 days
    • Tioconazole 6.5% applied vaginally x 1

Complicated

Severe or immunosuppressed

Non-albicans species

  • For example, C. glabrata, C. krusei and other atypical Candida spp.
  • Boric acid vaginal suppository intravaginal qday x ≥14 days
    • Can be fatal if taken orally
  • If empirically treated and later is found to have non-albicans Candida spp., no change in therapy is needed if patient is improving (otherwise switch to boric acid.

Recurrent (≥ 4 infections in a year)

  • Treat as for uncomplicated (see above)
  • Once therapy completed, prescribe long-term treatment
    • Fluconazole 150mg PO qweek x 6 months, OR
    • Intravaginal medication, such as clotrimazole 500mg PV qweek or 200mg PV twice a week

Pregnant Patients

  • Intravaginal clotrimazole or miconazole are the only recommended treatments
  • Duration is 7 days
  • PO fluconazole associated with congenital malformations and spontaneous abortions[4]

Disposition

  • Outpatient
    • Refer all "complicated" cases to gynecology

See Also

References

  1. Adapted from ACOG practice bulletin
  2. Kauffmann CA. Overview of Candida Infections. UptoDate. 2016.
  3. Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 62:e1.
  4. Molgaard-Nielsen D et al. Association Between Use of Oral Fluconazole During Pregnancy and Risk of Spontaneous Abortion and Stillbirth. JAMA. 2016;315(1):58-67.